Currently, there are few abortion providers in North Simcoe Muskoka, and no service in Barrie, a large urban area, often necessitating travel to Toronto. Demand for services exceeds surgical providers. Limited rural abortion services can lead to delayed care and abortions at later gestations (Norman et al, 2016). About 30% of Canadian women have at least one abortion in their lifetime (Norman, 2012). From 2003-2013, the teen pregnancy rate has been decreasing in Simcoe County; the highest rates of teen pregnancy occur in Orillia and Midland, communities with the highest rates of poverty; 50% of pregnancies are unplanned (SMDHU HealthStats 2013). Medical abortion in Canada has been uncommon, at 3.9% of all abortions, using methotrexate with misoprostol; geographic disparities exist in the availability of services (Guilbert et al, 2016). Methotrexate is a more cumbersome and second-best method: the regimen is as effective as mifepristone and misoprostol for up to 7 weeks' gestation, but completion is less predictable, as some abortions are delayed several weeks after administration of methotrexate (Dunn & Cook, 2014). Methotrexate is teratogenic, thus not recommended by the WHO as associated with serious infant deformities if the abortion fails (Dunn and Cook, 2014). Methotrexate abortions are also labour-intensive for practitioners as necessitates following women over weeks to ensure the abortion is complete; thus, this method is not widely used in Canada (Dunn & Cook, 2014). In 2015, Health Canada approved Mifegymiso (mifepristone and misoprostol). A RCT reported that women find mifepristone to be more acceptable than methotrexate, reporting reduced pain and wait time for abortion completion (Wiebe et al, 2002). Strategies to support access include the development of regional care groups to provide medical abortions, professional training support, and improving practitioner and client access to information on pregnancy choices and services (ECHO: Recommendations to Improve Abortion Services in Ontario, 2011). Access is not expected to increase Canadian abortion rates, but may significantly improve access, women's health and wellbeing.
This project’s methods include reaching out to Primary Care Providers in North Simcoe Muskoka and conducting an estimated twenty key informant interviews with MDs, NPs, OBS/GYNs, Public Health, and local women with access experience. The interviews will assess provider interest in offering Mifegymiso, perceptions regarding barriers, and identify resources required to maintain a successful medical abortion service in general practice. Expected outcomes include interview analysis to develop a network of local providers with access to back-up surgical abortion services. Educational sessions will be offered increase provider knowledge about mifegymiso, local abortion services and availability, and to develop a provider support network. Service details will be promoted to regional health and social service providers. Media will be utilized to increase public awareness about local services. A report will be produced, summarizing our interview results, experience, and sustainability considerations to better inform the practices of Primary Care Providers in other regions in Ontario and beyond. Presentations at conferences will be pursued.
Principal Investigator
Dr. Angel Foster (University of Ottawa); Meghan Gyorffy (Orillia Soldiers' Memorial Hospital)
Collaborators
Pat Campbell (Orillia Soldiers' Memorial Hospital); Dr. Colin Lee (Simcoe Muskoka District Health Unit); Dr. Ashley MacDonald (Barrie Family Health Organization); Dr. Katherine Rheault (Orillia Soldiers' Memorial Hospital)
Share